Show simple item record

dc.contributor.authorGalán Ganga, M.
dc.contributor.authorRodríguez Cueto, C.
dc.contributor.authorMerchán Rubira, J.
dc.contributor.authorHernández, F.
dc.contributor.authorÁvila, J.
dc.contributor.authorPosada Ayala, María
dc.contributor.authorLanciego, J.L.
dc.contributor.authorLuengo, E.
dc.contributor.authorLópez, M. G.
dc.contributor.authorRábano, A.
dc.contributor.authorFernández Ruiz, J.
dc.contributor.authorLastres Becker, I.
dc.date.accessioned2021-07-22T11:27:54Z
dc.date.available2021-07-22T11:27:54Z
dc.date.issued2021
dc.identifier.issn2051-5960spa
dc.identifier.urihttp://hdl.handle.net/10641/2350
dc.description.abstractTauopathies are a group of neurodegenerative diseases characterized by the alteration/aggregation of TAU protein, for which there is still no effective treatment. Therefore, new pharmacological targets are being sought, such as elements of the endocannabinoid system (ECS). We analysed the occurrence of changes in the ECS in tauopathies and their implication in the pathogenesis. By integrating gene expression analysis, immunofluorescence, genetic and adeno-associated virus expressing TAU mouse models, we found a TAU-dependent increase in CB2 receptor expression in hippocampal neurons, that occurs as an early event in the pathology and was maintained until late stages. These changes were accompanied by alterations in the endocannabinoid metabolism. Remarkably, CB2 ablation in mice protects from neurodegeneration induced by hTAU P301L overexpression, corroborated at the level of cognitive behaviour, synaptic plasticity, and aggregates of insoluble TAU. At the level of neuroinflammation, the absence of CB2 did not produce significant changes in concordance with a possible neuronal location rather than its classic glial expression in these models. These findings were corroborated in post-mortem samples of patients with Alzheimer’s disease, the most common tauopathy. Our results show that neurons with accumulated TAU induce the expression of the CB2 receptor, which enhances neurodegeneration. These results are important for our understanding of disease mechanisms, providing a novel therapeutic strategy to be investigated in tauopathiesspa
dc.language.isoengspa
dc.publisherActa Neuropathological Communicationsspa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectCannabinoid receptorspa
dc.subjectAlzheimer’s diseasespa
dc.subjectNeurodegenerationspa
dc.subjectNeuroinflammationspa
dc.titleCannabinoid receptor CB2 ablation protects against TAU induced neurodegeneration.spa
dc.typearticlespa
dc.description.versionpost-printspa
dc.rights.accessRightsopenAccessspa
dc.description.extent8580 KBspa
dc.identifier.doi10.1186/s40478-021-01196-5spa
dc.relation.publisherversionhttps://actaneurocomms.biomedcentral.com/articles/10.1186/s40478-021-01196-5spa


Files in this item

FilesSizeFormatView
1.- Cannabinoid receptor CB2 ...8.378MbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España